Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Luye Approved to Launch Schizophrenia Drug in US

publication date: Jul 29, 2024

Yantai Luye Pharma was approved for a US launch of Erzofri®, a once-monthly extended release drug for schizophrenia and schizoaffective disorder. The company said antipsychotic medications can control symptoms of schizophrenia, but patient adherence to antipsychotics is generally poor, creating a window for the once-monthly drug. Erzofri is the first patented paliperidone palmitate long-acting injection developed in China that is approved in the US. Its patent will expire in 2039. Erzofri was approved as a new drug under the 505(b) (2) pathway in the US. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here